Loading provider…
Loading provider…
Neurology Physician in Saint Louis, MO
NPI: 1447276662Primary Practice Location
BARNES JEWISH HOSPITAL
1 Barnes Jewish Hospital Plz, Saint Louis, MO
Primary Employer
Washington University School of Medicine
surgery.wustl.edu
HQ Phone
Get MD Barbara's Phone Numberphone_androidMobile
Get MD Barbara's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardMO State Medical License
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 96138Administration of psychological or neuropsychological test by technician, first 30 minutes | 89 | 91 |
| 2 | 99215Established patient office or other outpatient, visit typically 40 minutes | 78 | 80 |
| 3 | G2212Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 34 | 43 |
| 4 | 99205New patient office or other outpatient visit, typically 60 minutes | 32 | 32 |
| 5 | 96132Evaluation of neuropsychological test, first hour | 16 | 16 |
Association Between Socioeconomic Factors, Race, and Use of a Specialty Memory Clinic.
Authors: Tang, Bingrong, Cai, Jingjing, Sun, Lin, Li, Yiping, Qu, Jia, Snider, Barbara Joy, Wu, Shengzhou
Journal: PLoS One
Publication Date: 2014-07-25
Lead Sponsor: Washington University School of Medicine
Collaborators: National Institute on Aging (NIA), Alzheimer's Association, Eisai Inc., Accelerating Medicines Partnership (AMP)
Intervention / Treatment: DRUG: Lecanemab, DRUG: Matching Placebo (E2814), DRUG: E2814
Lead Sponsor: Biogen
Intervention / Treatment: DRUG: Placebo, DRUG: Aducanumab (BIIB037)
Lead Sponsor: Eli Lilly and Company
Intervention / Treatment: DRUG: Placebo, DRUG: LY3202626, DRUG: Donanemab